My guest in this episode is Dr. Mohit Jain, founder and CSO of Sapient.
Dr. Jain is a physician-scientist with more than 20 years of expertise in physiology, computational biology, and mass spectrometry-based bioanalytics. He formed the Jain Laboratory at UCSD, where he led his team to develop next-generation mass spectrometry systems to probe the non-genetic landscape of disease across large-scale human studies. He founded Sapient in 2021 as a spinout of the Jain Laboratory to expand upon this mission, providing bespoke services multi-omics biomarker discovery.
In this wide ranging yet focused interview, we discuss - Biomarkers and how their role has changed - The predictor for a clinical trial success - Precision guided medicine - The change in disease classification over last 20 years - Genetic vs non-genetic reasons for disease - Next generation mass spectrometry and - Different disease expression in different people
I enjoyed my chat with Dr. Jain, particularly his ability to simplify complex problems the pharma industry is facing and what should be done about it. Hope you do too.
Here's Dr. Mohit Jain.